Frequently asked questions

Hormone replacement therapy may help when symptoms are related to hormonal decline, hormonal imbalance, or inadequate hormone signaling. In women, this may involve estrogen deficiency, progesterone deficiency, testosterone deficiency, or patterns sometimes described as “estrogen excess” or relative progesterone deficiency.

Estrogen deficiency may contribute to hot flashes, night sweats, vaginal dryness, painful intercourse, sleep disruption, mood changes, and changes in bone health. Progesterone deficiency or inadequate progesterone effect may contribute to poor sleep, night sweats, irritability, anxiety, PMS-like symptoms, and difficulty feeling calm or restored. Testosterone deficiency in women may contribute to low sexual desire, reduced arousal, difficulty with orgasm, low motivation, reduced energy, decreased muscle recovery, and reduced overall vitality.

Symptoms of relative estrogen excess may include breast tenderness, bloating, fluid retention, mood swings, heavier or irregular bleeding, irritability, headaches, or worsening PMS-type symptoms. In those situations, treatment is not simply “more estrogen.” The goal is to evaluate the full hormone pattern and determine whether progesterone support, estrogen adjustment, thyroid treatment, metabolic support, or other interventions are needed.

At Dynamic Psychiatry & Wellness, hormone replacement therapy is not based on symptoms alone or lab values alone. We evaluate symptoms, labs, sleep, mood, libido, body composition, menstrual or bleeding patterns, metabolic health, thyroid function, and overall response. The goal is to restore balance and improve function while maintaining safety through individualized monitoring and adjustment.

Reference links:

ACOG: Hormone Therapy for Menopause

NAMS 2022 Hormone Therapy Position Statement

Global Consensus Position Statement on Testosterone Therapy for Women

ISSWSH Clinical Practice Guideline for Testosterone in Women with HSDD

Micronized Progesterone and Sleep Systematic Review

Oral Micronized Progesterone Trial in Perimenopausal Women

Many concerns about hormone therapy come from older studies, older hormone formulations, or incomplete explanations of risk. In these older studies, we didn't understand as much as today and the hormones were obtained from horses or pigs. These horse and pig hormones were very different than the ones made by humans and we didn't realize how they affected the body. Therefore, older studies showed some increased risks with using animal hormones and not understanding how some hormones balance each other out. Since we understand hormones a lot better and because today's hormones are bioidentical the risks are much lower than they were previously. (Bioidentical means the hormones are generally identical to what your body already makes.)

One of the most important examples involves estrogen and the uterus. Estrogen was previously used by itself in women with an intact uterus. Estrogen alone was unbalanced and often stimulated the inner lining of the uterus (endometrium) to grow really thick. Sometimes this increased the risk of endometrial cancer over time. That concern was real and still should not be dismissed as a thing of the past.

However, that is not the same as saying all hormone therapy carries the same uterine risk.

The major clinical distinction is whether estrogen is adequately balanced by progesterone or another progestogen when the uterus is still present. Adequate progesterone/progestogen exposure is used to protect the uterus by limiting how thick the endometrium becomes (on the inside of the uterus) when estrogen is prescribed. This is always a consideration at Dynamic Psychiatry and Wellness.

This is why hormone therapy should be guided by a clinician who understands the difference between unopposed estrogen, inadequate progesterone exposure, and properly monitored combined hormone therapy.

For patients with a uterus, progesterone is often used with systemic estrogen to protect the uterine lining from growing dangerously thick.

The concern is not simply “estrogen causes cancer.” The concern is estrogen without inadequate progesterone/progestogen to balance it out.

Research over several decades has shown that estrogen alone increases endometrial cancer risk in women with an intact uterus, while adding adequate progestogen/progesterone changes that risk profile substantially.

For example, the Women’s Health Initiative follow-up found that continuous combined estrogen plus progestin was associated with lower endometrial cancer incidence compared with placebo. Earlier observational and regimen studies also supported the principle that adequate progestogen exposure is the key protective factor.

This is why we do not treat hormone therapy as a casual wellness product. Hormones are powerful medical tools that should be prescribed within a structured plan.

Reference links:

Women’s Health Initiative follow-up: continuous combined estrogen plus progestin and endometrial cancer

NAMS 2022 Hormone Therapy Position Statement

Jick et al., 1993, estrogen and progestogen regimens

Pike et al., 1997, progestin duration and endometrial cancer risk

Weiderpass et al., 1999, estrogen-progestin replacement and endometrial cancer risk

In many cases, yes, but the plan should be individualized.

The major concern with GLP-1 medications is delayed gastric emptying, which may affect the timing or absorption of some oral medications. This is generally a practical prescribing issue, not evidence of a dangerous class-wide interaction with hormone therapy. In other words, it is relatively simple to manage this by using injections or creams instead of oral pills for estrogen.

Transdermal estrogen, like the creams, avoids much of the oral absorption issue. Oral progesterone are still often used with GLP-1 medications, but timing of when to take the pill must be part of the treatment plan. Additionally, symptoms, menstrual bleeding patterns, and response should be monitored.

Reference links:

2024 systematic review: GLP-1 receptor agonists and oral medications

Semaglutide and combined oral contraceptive pharmacokinetics

British Menopause Society: incretin-based therapies and HRT

Not necessarily.

Estrogen used by itself in a woman with an intact uterus can increase the risk of endometrial hyperplasia and endometrial cancer over time but we don't use estrogen by itself at Dynamic Psychiatry & Wellness. We always include the protective influence of progesterone with estrogen.

The cancer concern has been shown to be mainly with estrogen alone or inadequate progesterone/progestogen doses, not with all properly monitored hormone therapy that includes estrogen.

See the "Why Do Hormone Therapy Safety Concerns Exist?" question for more details.

Reference links:

NAMS 2022 Hormone Therapy Position Statement

WHI follow-up on continuous combined estrogen plus progestin

Many patients are interested in bioidentical hormone therapy because the hormones are structurally identical to hormones naturally produced by the body.

That distinction may matter, but “bioidentical” does not automatically mean risk-free.

Safety depends on the full treatment plan, including:

• Hormone type

• Dose

• Route of administration

• Progesterone/progestogen exposure

• Whether the patient has a uterus

• Symptoms and response

• Bleeding patterns

• Medical history

• Ongoing monitoring

• Individual risk factors

A bioidentical estrogen regimen still needs appropriate progesterone support when the uterus is present. A compounded hormone regimen still needs careful dosing and monitoring. A patient’s symptoms and clinical response still matter.

At Dynamic Psychiatry & Wellness, we use bioidentical hormone therapy within a physician-guided framework rather than treating the word “bioidentical” as a substitute for medical judgment.

Some patients ask whether estrogen and progesterone should be placed together in the same cream.

In many cases, we prefer a different approach.

Estrogen and testosterone are often used earlier in the day because they may support energy, mood, libido, vitality, and performance. Progesterone is often taken at night because it can have calming effects and may support sleep quality in some patients.

For that reason, many patients benefit from separating morning estrogen/testosterone from nighttime progesterone rather than combining everything into one cream.

This approach also allows us to provide progesterone in a way that is more intentionally dosed for endometrial protection and symptom response when clinically appropriate.

This is not simply about hormone numbers. It is about how the patient feels, sleeps, responds, and functions over time.

Reference links:

Micronized progesterone and sleep systematic review

Oral micronized progesterone trial in perimenopausal women

Scientific Reports: oral micronized progesterone, night sweats, and sleep

There is some truth to patient concerns about premixed hormone creams.

If a premade cream contains fixed amounts of estrogen and progesterone, the progesterone amount may not be adequate for every patient. That can be especially concerning if estrogen exposure is meaningful and progesterone exposure is too low or unreliable.

At Dynamic Psychiatry & Wellness, we are not limited to premade, fixed-dose hormone combinations.

When compounded creams are used, we work with reputable compounding pharmacies that allow individualized dosing. If estrogen dosing appears appropriate but progesterone support is not adequate, the regimen can be adjusted rather than forcing the patient into a fixed formula.

That said, we often prefer oral progesterone at night when clinically appropriate because it may better support sleep and provide more intentional progesterone exposure.

The larger point is this: hormone therapy should be adjustable. Patients should not be locked into a premade formula that cannot respond to symptoms, physiology, or clinical needs.

Reference links:

British Menopause Society: progestogens and endometrial protection

NAMS 2022 Hormone Therapy Position Statement

Some patients worry that hormone therapy cannot be used with GLP-1 medications such as Semaglutide or Tirzepatide or Retatrutide.

Current evidence does not suggest a dangerous class-wide interaction between GLP-1 medications and estrogen/progesterone therapy. The main concern is usually practical: GLP-1 medications slow gastric emptying, which may affect the timing or absorption of some oral medications.

This is one reason route and formulation matter.

Transdermal estrogen creams avoid much of the oral absorption concern. Oral progesterone can still be considered, but dosing, timing, symptoms, bleeding patterns, and clinical response should be monitored.

For patients using tirzepatide, the absorption question may deserve extra attention because tirzepatide can have a stronger gastric-emptying effect, especially during dose escalation. This does not mean hormone therapy cannot be used. It means the regimen should be prescribed thoughtfully and we may avoid oral estrogen.

At Dynamic Psychiatry & Wellness, GLP-1 medications and hormone therapy can be safely coordinated as part of a broader metabolic and hormone optimization plan when clinically appropriate.

Reference links:

2024 systematic review: GLP-1 receptor agonists and oral medications

Semaglutide and combined oral contraceptive pharmacokinetics

Semaglutide study full text

British Menopause Society: incretin-based therapies and HRT

Not usually. Estrogen is not generally considered a “weight gain hormone.”

In women, estrogen plays important roles in healthy metabolism, approriate fat distribution, insulin sensitivity, energy regulation, and body composition. During perimenopause and menopause, declining estrogen is often associated with changes in body composition, including increased central or visceral fat accumulation in many women.

That does not mean estrogen therapy is a weight-loss medication. For many patients, automatically blaming the weight gain, insulin resistance, sleep disruption, stress physiology, thyroid dysfunction, low testosterone, menopause-related hormone changes would not be the approriate first step. Intead we look at all those thinga and include medication effects before making conclusions or treatment plans. Then once all of these things are understood, we can make those decisions.

This is one reason hormone therapy and GLP-1 treatment may be used together in selected patients as part of a coordinated plan addressing appetite regulation, insulin resistance, body composition, hormone balance, and long-term metabolic health.

Reference links:

Menopausal hormone therapy and visceral adiposity

Estrogen deficiency and obesity during menopause

The role of estrogen in insulin resistance

Hormone therapy should not be managed by labs alone.

Laboratory testing is important, but symptoms, sleep, mood, libido, bleeding patterns, energy, weight, body composition, side effects, and overall clinical response are also essential.

At Dynamic Psychiatry & Wellness, hormone therapy may be monitored through:

• Clinical symptoms and response

• Laboratory testing

• Menstrual or bleeding patterns when relevant

• Sleep and energy changes

• Libido and sexual wellness response

• Mood and anxiety symptoms

• Weight and body composition

• Metabolic markers

• Thyroid function

• Side effects or signs of imbalance

• Ongoing dose adjustment

We do not treat lab values as the only source of truth. Labs provide important information, but patients live in their bodies every day. Their symptoms and response matter.

The goal is not to force every patient into a predetermined hormone number. The goal is to use medical data, clinical judgment, and patient response together to support safe, individualized care.

No.

Labs are important, but they are not the whole story.

Hormone therapy should be guided by laboratory data, symptoms, side effects, sleep, mood, libido, bleeding patterns, energy, body composition, and the patient’s overall response.

At Dynamic Psychiatry & Wellness, we use labs as one part of a broader clinical picture.

Progesterone is commonly used with systemic estrogen in women who still have a uterus because it helps protect the uterine lining from too much estrogen stimulation.

Without adequate progesterone, the endometrium may become overstimulated over time and this increases the risk of various long term problems.

This is why hormone therapy should be balanced, individualized and monitored rather than treated as a generic wellness product.

Reference links:

British Menopause Society: progestogens and endometrial protection

NAMS 2022 Hormone Therapy Position Statement

Sometimes, but not always.

The concern is that premade, fixed-dose creams may not provide enough progesterone for every patient. Progesterone exposure must be adequate, reliable, and matched to the estrogen dose and the patient’s clinical situation.

At Dynamic Psychiatry & Wellness, we often prefer separating estrogen/testosterone from nighttime oral progesterone when clinically appropriate. This allows progesterone to be dosed more intentionally and may also support sleep.

When compounded creams are used, we use reputable compounding pharmacies that allow individualized dosing rather than relying only on premade fixed combinations.

Reference links:

British Menopause Society: progestogens and endometrial protection

British Menopause Society / Women’s Health Concern HRT recommendations

Progesterone can have calming effects and may support sleep quality in some patients.

Because estrogen and testosterone may support energy, mood, libido, and vitality, they are often used earlier in the day. Progesterone is often taken at night because that timing may better match its calming or sleep-supporting effects.

This is one reason we often separate estrogen/testosterone from progesterone rather than combining everything into one morning cream.

Reference links:

Micronized progesterone and sleep systematic review

Oral micronized progesterone trial in perimenopausal women

Estrogen is not simply a fat-gain hormone.

In women, estrogen helps regulate metabolism, fat distribution, insulin sensitivity, and body composition. During menopause and perimenopause, declining estrogen is often associated with increased central fat accumulation and metabolic changes.

Hormone therapy is not a substitute for nutrition, exercise, sleep, metabolic treatment, or weight-management care. However, it may be part of a coordinated plan when hormone changes are contributing to symptoms, body composition changes, or metabolic dysfunction.

Reference links:

Menopausal hormone therapy and visceral adiposity

Estrogen deficiency and obesity during menopause

The role of estrogen in insulin resistance